ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings
  • Abstract Number: 1837 • 2013 ACR/ARHP Annual Meeting

    Three-Dimension Culture Of Mesenchymal Stem Cells With Nano-Fiber Scaffold Induces Chondrogenesis and Osteogenesis

    Kunihiro Yamaoka1, Koshiro Sonomoto1, Xiangmei Zhang1, Masahiro Kondo1, Shunsuke Fukuyo1, Makoto Satake2, Hiroaki Kaneko2, Kazuhisa Nakano1, Yosuke Okada1 and Yoshiya Tanaka1, 1The First Department of Internal Medicine, University of Occupational and Environmental Health, Japan, Kitakyushu, Japan, 2The Third Laboratory, Integrative Technology Research Institute, Teijin Limited, Tokyo, Japan

    Background/Purpose: Development of biologics has made remission a realistic treatment goal in treatment of rheumatoid arthritis (RA). However, once bone or cartilage is destructed treatment…
  • Abstract Number: 1838 • 2013 ACR/ARHP Annual Meeting

    The Use Of Three-Dimensionally Printed β-Tricalcium Phosphate/Hydroxyapatite To Understand The Regulation Of Adenosine Receptors In Osteoclast Formation and Promotion In Bone Regeneration

    Stephanie Ishack1, Aranzazu Mediero1, Tuere Wilder2, John Ricci3 and Bruce N. Cronstein4, 1Medicine, Division of Translational Medicine, NYU School of Medicine, New York, NY, 2Medicine, division of Translational Medicine, NYU School of Medicine, New York, NY, 3Biomaterials, NYU Dental School, New York, NY, 4Internal Medicine, NYU School of Medicine, Division of Rheumatology, New York, NY

    Background/Purpose: Bone defects resulting from trauma or infection need timely and effective treatments to replace damaged bone. Using specialized three-dimensional (3-D) printing technology, combined with…
  • Abstract Number: 1839 • 2013 ACR/ARHP Annual Meeting

    Osteoclastogenesis Is Enhanced By Synovial Fluid Derived Anti-Citrullinated Proteins Antibodies In Rheumatoid Arthritis

    Akilan Krishnamurthy1, Heidi Wähämaa1, Vijay Joshua1, Catia Cerqueira1, Elena Ossipova2, Nancy Vivar Pomiano3, Karin Lundberg2, Vivianne Malmström4, Per-Johan Jakobsson5, Lars Klareskog5, Georg Schett6, Jimmy Ytterberg1 and Anca I Catrina5, 1Medicine, Rheumatology Unit, Karolinska University Hospital, Karolinska Institutet, Stockholm, Sweden, 2Rheumatology unit, Karolinska University Hospital, Karolinska Institutet, Stockholm, Sweden, 3Rheumatology unit, Karolinska University Hospital, Karolinska Institute, Stockholm, Sweden, 4Rheumatology Unit, Department of Medicine, Karolinska University Hospital, Solna, Karolinska Institutet, Stockholm, Sweden, 5Medicine, Rheumatology unit, Karolinska University Hospital, Karolinska Institute, Stockholm, Sweden, 6Dept of Medicine 3, Rheumatology and Clinical Immunology, University of Erlangen-Nuremberg, Erlangen, Germany

    Background/Purpose: Anti citrullinated modified vimentin antibodies isolated from peripheral blood (PB) of RA patients induce osteoclasts (OC) formation from PB derived monocytes of healthy individuals.…
  • Abstract Number: 1840 • 2013 ACR/ARHP Annual Meeting

    Increased Expression of BAFF Receptor On Monocytes Is a Contributory Factor of Hypergammaglobulinemia in Patients With Primary Sjögren’s Syndrome

    Keiko Yoshimoto1, Maiko Tanaka2, Masako Kojima2, Hideko Ogata2, Eriko Ishioka3, Ayumi Nishikawa2, Katsuya Suzuki1, Hideto Kameda1, Tohru Abe4 and Tsutomu Takeuchi5, 1Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan, 2Division of Rheumatology and Clinical Immunology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan, 3Division of Rheumatology, Department of Internal medicine, Keio University School of Medicine, Tokyo, Japan, 4Dept Int Med Saitama Med Ctr, Saitama Medical School, Kawagoe-shi Saitama, Japan, 5Keio University School of Medicine, Tokyo, Japan

    Background/Purpose: BAFF (B cell stimulation factor belonging to TNF family) is a cytokine which is mainly produced by monocytes, dendritic cells and T cells. We…
  • Abstract Number: 1841 • 2013 ACR/ARHP Annual Meeting

    BAFF Induces Production of Matrix Metalloproteinase-9 By Peripheral Monocytes in Patients With Primary Sjögren’s Syndrome Through a Signaling Pathway That Involves NF-Kb and PI3 Kinase

    Keiko Yoshimoto1, Maiko Tanaka2, Masako Kojima2, Hideko Ogata2, Eriko Ishioka3, Ayumi Nishikawa2, Katsuya Suzuki1, Hideto Kameda1, Tohru Abe4 and Tsutomu Takeuchi5, 1Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan, 2Division of Rheumatology and Clinical Immunology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan, 3Division of Rheumatology, Department of Internal medicine, Keio University School of Medicine, Tokyo, Japan, 4Dept Int Med Saitama Med Ctr, Saitama Medical School, Kawagoe-shi Saitama, Japan, 5Keio University School of Medicine, Tokyo, Japan

    Background/Purpose: B cell activating factor of the TNF family (BAFF) regulates proliferation, differentiation and survival of B cells, and plays a pivotal role in the…
  • Abstract Number: 1842 • 2013 ACR/ARHP Annual Meeting

    Pathophysiological Effects Of Free Fatty Acids On Key Cells Of Arthritis

    Klaus W. Frommer1, Andreas Schäffler2, Stefan Rehart3, Angela Lehr4, Ulf Müller-Ladner1 and Elena Neumann5, 1Internal Medicine and Rheumatology, Justus-Liebig-University of Gießen, Kerckhoff-Klinik, Bad Nauheim, Germany, 2Department of Internal Medicine III, Endocrinology, Diabetes, Metabolism, Justus-Liebig-University of Giessen, Giessen, Germany, 3Orthopedics and Trauma Surgery, Markus-Hospital, Frankfurt, Germany, 4Dept Orthopedics and Trauma Surgery, Markus-Hospital, Frankfurt, Germany, 5Department of Internal Medicine and Rheumatology, Justus-Liebig-University of Gießen, Kerckhoff-Klinik, Bad Nauheim, Germany

    Background/Purpose:  Although obesity, a known risk factor for arthritic diseases, increases mechanical stress on joints, it appears not to be the only factor being responsible…
  • Abstract Number: 1843 • 2013 ACR/ARHP Annual Meeting

    Treatment With Staphyloccocal Protein A Which Is Immuno-Modulatory In The Murine Collagen Arthritis Model, Does Not Increase Infection Severity In Murine Listeria Or Candida Challenge Models, In Contrast To Anti-TNF Treatment

    Edward Bernton1 and Valerie Lowe2, 1Protalex Inc., Summit, NJ, 2Washington Biotechnology, Inc., Baltimore, MD

    Background/Purpose: PRTX-100 is a highly-purified GMP staphylococcal protein A (SpA) that  is currently in Phase I trials in patients with active rheumatoid arthritis (RA).  SpA…
  • Abstract Number: 1844 • 2013 ACR/ARHP Annual Meeting

    Rheumatoid Arthritis, Sjogren’s Syndrome and Systemic Lupus Erythematosus Patients Have a Distinct Spectrum Of Serum Anticytokine Autoantibodies

    Sarthak Gupta1,2, Ioanna P. Tatouli3, Lindsey B. Rosen2, Sarfaraz A. Hasni1, Richard M. Siegel1, Steven M. Holland2, Haralampos M. Moutsopopoulos3 and Sarah K. Browne2, 1National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, 2Laboratory of Clinical Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, 3School of Medicine, National University of Athens, Athens, Greece

    Background/Purpose: Anticytokine autoantibodies are pathogenic in many hematologic, pulmonary and infectious diseases. However, the prevalence and significance of anticytokine autoantibodies in rheumatic conditions is poorly…
  • Abstract Number: 1845 • 2013 ACR/ARHP Annual Meeting

    Soluble Type I Interferon Receptor 2 Is Elevated By Interferon Treatment and In Certain Autoimmune Diseases

    Taher Fatakdawala1, Michael Skawinski1, Jonathan Ferriera2, Tara Stauffer1 and Thomas Lavoie1, 1Product Research & Development and Assay Services, PBL Assay Science, Piscataway, NJ, 2Quality Control, PBL Assay Science, Piscataway, NJ

    Background/Purpose: The Type I Interferon (IFN) receptor is a heterodimer of chain 1 (IFNAR1) which is required for signaling, and chain 2 (IFNAR2) which binds…
  • Abstract Number: 1846 • 2013 ACR/ARHP Annual Meeting

    Mitochondrial Dysfunction Induces An Inflammatory, Tissue-Degrading, and Angiogenic Response In Normal Human Synoviocytes

    M. Noa Valcárcel-Ares1, Romina R. Riveiro-Naveira1, Jesus Loureiro1, Carlos Vaamonde-García1, Laura Hermida-Carballo1, Francisco J. Blanco2 and Maria J. López-Armada1, 1Aging and Inflammation Research Lab, INIBIC-CHU A Coruña, A Coruña, Spain, 2Osteoarticular and Aging Res. Lab. CIBER-BBN. INIBIC- University of A Coruña, A Coruña, Spain

    Background/Purpose: Tissues affected with inflammatory arthritis (IA) are subjected to great levels of oxidative stress. Synoviocytes from IA patients present a higher rate of mitochondrial…
  • Abstract Number: 1847 • 2013 ACR/ARHP Annual Meeting

    Certolizumab-Pegol Induces Reverse Signaling Through Membrane TNF Via Calcineurin Activation In Human Monocytes. Relevance In Inflammation

    Jean-Frederic Boyer1,2, Michel Baron3, Delphine Nigon1, Arnaud L. Constantin1, Alain G. Cantagrel1,2 and Jean-Luc Davignon2,4, 1Rheumatology, Purpan University Hospital, Toulouse Cedex 9, France, 2INSERM CNRS UMR 1043, Paul Sabatier University Toulouse, Toulouse, France, 3Centre de Physiopathologie de Toulouse Purpan, INSERM CNRS UMR 1043, Paul Sabatier University Toulouse, Toulouse, France, 4Rheumatology, Purpan University Hospital, Toulouse, France

    Background/Purpose: Reverse signalling seems to play a role in the mode of action of anti-TNF-α agents but this pathway and its relevance are poorly understood.…
  • Abstract Number: 1813 • 2013 ACR/ARHP Annual Meeting

    Evaluation Of The Effect Of Sildenafil On The Microvascular Blood Flow and On The Endothelial Progenitor Cells In Patients With Early Systemic Sclerosis: A Randomized, Double-Blind, Placebo-Controlled Study

    Fernando V. Andrigueti, Pâmela C.C. Ebbing, Maria I. Arismendi and Cristiane Kayser, Rheumatology Division, Universidade Federal de São Paulo, São Paulo, Brazil

    Background/Purpose: Phosphodiesterase-5 inhibitors have been successfully used for the treatment of Raynaud’s phenomenon (RP) in patients with systemic sclerosis (SSc). However, no study has evaluated…
  • Abstract Number: 1808 • 2013 ACR/ARHP Annual Meeting

    Impact Of Baseline Disease Severity and Treatments On Outcomes In Clinical Trials Of SLE:  Results From The Soccit Program

    Kenneth C. Kalunian1, Mimi Kim2, Timothy W. Behrens3, Sabine Bongardt4, Paul Brunetta5, Paola Daly6, Nathalie Franchimont7, Richard Furie8, Matthew Linnik9, Bevra H. Hahn10, Leslie M. Hanrahan11, Jan L. Hillson12, Jane Salmon13, Neil Solomons14 and Joan T. Merrill15, 1UCSD School of Medicine, La Jolla, CA, 2Epidemiology and Population Health, Albert Einstein College of Medicine, Bronx, NY, 3Genentech, Inc, South San Francisco, CA, 4UCB Pharma, Monheim, Germany, 5Biotherapeutics, Genentech, So San Francisco, CA, 6Lupus Foundation of America, Washington DC, DC, 7Biogen Idec Inc., Weston, MA, 8North Shore-LIJ Health System, Lake Success, NY, 9Lilly Research Laboratories, La Jolla, CA, 10Rheumatology, UCLA David Geffen School of Medicine, Los Angeles, CA, 11Education & Research, Lupus Foundation of America, Washington, DC, 12Bristol-Myers Squibb, Seattle, WA, 13Rheumatology, Hospital for Special Surgery, New York, NY, 14Vifor Pharma, New York, NY, 15Department of Clinical Pharmacology, Oklahoma Medical Research Foundation, Oklahoma City, OK

    Background/Purpose: The Lupus Foundation of America Collective Data Analysis Initiative was established to evaluate SLE clinical trial design, using data collected from multiple studies.  To…
  • Abstract Number: 1809 • 2013 ACR/ARHP Annual Meeting

    Topline Results Of The Biomarkers Of Lupus Disease (BOLD) Study: Clinical and Mechanistic Perplexities Of Lupus Treatment Trials Can Be Mitigated By Eliminating Background Immune Suppressants

    Joan T. Merrill1, Frederick W. Immermann2, Tianhui Zhou3, Margot O'Toole4, Maryann Whitley5, Andrew A. Hill5, Ying Zhang5, David von Schack5, Padmalatha S. Reddy5, Jaime L. Masferrer4, Stan Kamp1, Joel M. Guthridge6, Aikaterini Thanou7, Paul Wu5, Theresa Paradis5, William M. Mounts5, Judith A. James8 and Sudhakar T. Sridharan2, 1Clinical Pharmacology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, 2BioTherapeutics R&D, Pfizer Inc, Collegeville, PA, 3BioTherapeutics R&D, Bristol Myers Squibb, Princeton, NJ, 4independent consultant, Cambridge, MA, 5Pfizer Inc, Cambridge, MA, 6Arthritis and Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, 7Arthritis and Clinical Immmunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, 8Oklahoma Medical Research Foundation, Oklahoma City, OK

    Background/Purpose: The BOLD study was designed to test the discriminatory capacity and safety of a trial design eliminating background immune suppressants (IS) in SLE patients…
  • Abstract Number: 1810 • 2013 ACR/ARHP Annual Meeting

    Evaluation Of The New American College Of Rheumatology/European League Against Rheumatism Criteria For The Classification Of Systemic Sclerosis In The Canadian Scleroderma Research Group Cohort

    Hebah Alhajeri1, Marie Hudson2, Marvin J. Fritzler3, Janet E. Pope4, Canadian Scleroderma Research Group -5 and Murray Baron6, 1Rheumatology, McGill University, Montreal, QC, Canada, 2Rheumatology, Lady David Institute for Medical Research and Jewish General Hospital, Montreal, QC, Canada, 3Medicine, University of Calgary, Calgary, AB, Canada, 4St Joseph Health Care, London, ON, Canada, 5Jewish General Hospital, Montreal, QC, Canada, 6Pavillion A, Rm 216, Lady David Institute for Medical Research and Jewish General Hospital, Montreal, QC, Canada

    Background/Purpose: New classification criteria for systemic sclerosis (SSc) have recently been developed. In this study, we aimed to assess the sensitivity of this classification in…
  • « Previous Page
  • 1
  • …
  • 2127
  • 2128
  • 2129
  • 2130
  • 2131
  • …
  • 2425
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology